ArticleThoracic cancer2021

Heterogeneous tumor-immune microenvironments between primary and metastatic carcinoid tumors differentially respond to anti-PD-L1 antibody therapy.

Shinya Sakata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.